Literature DB >> 23514115

Consensus guidelines for the diagnosis and treatment of multiple sclerosis.

B Yamout1, R Alroughani, M Al-Jumah, S Khoury, N Abouzeid, M Dahdaleh, I Alsharoqi, J Inshasi, S Hashem, M Zakaria, K ElKallab, T Alsaadi, T Tawfeek, S Bohlega.   

Abstract

The diagnosis of multiple sclerosis (MS) is dependent on the presence of clinical and paraclinical evidence demonstrating dissemination of central nervous system lesions in both space and time, as well as the exclusion of other disorders. Diagnostic criteria were originally promulgated in 1965 by the Schumacher committee and modified subsequently by the Poser committee to include paraclinical evidence. The most recent criteria are the 2010 modifications of the 2001 McDonald criteria, which are focused on making an earlier diagnosis of MS. This article provides guidelines, derived from clinical experience as well as evidence-based medicine, for the diagnosis and management of MS with special emphasis on practices in the Middle East.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23514115     DOI: 10.1185/03007995.2013.787979

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Magnetic resonance diffusion tensor imaging for occult lesion detection in multiple sclerosis.

Authors:  Jiafeng Chen; Chunkui Zhou; Lijun Zhu; Xiuli Yan; Yonghong Wang; Xin Chen; Shaokuan Fang
Journal:  Exp Ther Med       Date:  2016-12-02       Impact factor: 2.447

2.  Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.

Authors:  Jianzhen Shi; Xiaohui Wu; Yanmei Chen
Journal:  PLoS One       Date:  2019-09-12       Impact factor: 3.240

3.  Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.

Authors:  Jasem Al-Hashel; Samar F Ahmed; Raed Behbehani; Raed Alroughani
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 6.497

Review 4.  Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Authors:  Jose Eustasio Meca-Lallana; Rocío Hernández-Clares; Ester Carreón-Guarnizo
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.